While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. Expert Opinion on Pharmacotherapy. Accepted June 6 ...

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there ...

Management of older adults with type 2 diabetes and chronic kidney disease is complex. These individuals often have multiple comorbidities, take several medications, and are at increased risk of ...